Excitement among patients and researchers as custom-built jabs enter phase 3 trial
Doctors have begun trialling in hundreds of patients the world’s first personalised mRNA cancer vaccine for melanoma, as experts hailed its “gamechanging” potential to permanently cure cancer.
Melanoma affects about 132,000 people a year globally and is the biggest skin cancer killer. Currently, surgery is the main treatment although radiotherapy, medicines and chemotherapy are also sometimes used.
Now experts are testing new jabs that are custom-built for each patient and tell their body to hunt down cancer cells to prevent the disease ever coming back.
A phase 2 trial found the vaccines dramatically reduced the risk of the cancer returning in melanoma patients. Now a final, phase 3, trial has been launched and is being led by University College London Hospitals NHS Foundation Trust (UCLH).
Dr Heather Shaw, the national coordinating investigator for the trial, said the jabs had the potential to cure people with melanoma and are being tested in other cancers, including lung, bladder and kidney.
Believe me, those people are very willing to die on that hill with their hands wrapped firmly around their delusions. We saw that umpteen times during the worst of Covid. They are only going to get more unhinged about new mRNA vaccines.